The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases
Drug Resistance Updates · 2023-05 · 68 · 100958
DOI: 10.1016/j.drup.2023.100958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2023-05. Verfasst von Xueqing Hu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Pathology, Uni…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIH.
Abstract (Originalsprache)
AIM: While most patients with RET-altered cancer responded to the RET protein tyrosine kinase inhibitors (TKIs) pralsetinib (BLU667) and selpercatinib (LOXO292), few achieved a complete response. Heterogeneity in residual tumors makes it difficult to target their diverse genetic alterations individually. The aim of this study is to characterize the cancer cells that persist under continuous RET TKI treatment and identify the shared vulnerability of these cells. METHODS: We analyzed residual RET-altered cancer cells under prolonged RET TKI treatment by whole exome sequencing (WES), RNA-seq analysis, and drug-sensitivity screening. These were followed by tumor xenograft experiments of mono- and combinational drug treatments. RESULTS: BLU667- and LOXO292-tolerated persisters were cellularly heterogeneous, contained slowly proliferating cells, regained low levels of active ERK1/2, and displayed plasticity in growth rate, which we designated as in the transition state of resistance (TSR). TSR cells were genetically heterogeneous. Aurora A/B kinases were among the most significantly upregulated genes and that the MAPK pathway activity had significantly higher transcript footprints. MEK1/2 and Aurora kinase inhibitors were the most effective drugs when combined with a RET kinase inhibitor. In a TSR tumor model, combination of BLU667 with an Aurora kinase or a MEK1/2 kinase inhibitor caused TSR tumor regression. CONCLUSION: Our experiments reveal that the heterogeneous TSR cancer cells under continuous RET TKI treatment converge on the targetable ERK1/2-driven Aurora A/B kinases. The discovery of the targetable convergent point in the genetically heterogeneous TSR points to an effective combination therapy approach to eliminate the residual tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, U…
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NIH
- NCI
- Presbyterian Health Foundation
- Oklahoma Center for the Advancement of Science and Technology
Zitieren
APA
Hu, X., Liu, X., Khatri, U., & Wu, J. (2023). The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases. Drug Resistance Updates, 68, 100958. https://doi.org/10.1016/j.drup.2023.100958
Vancouver
Hu X, Liu X, Khatri U, Wu J. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases. Drug Resistance Updates. 2023;68:100958. doi:10.1016/j.drup.2023.100958
BibTeX
@article{Hu2023,
author = {Hu, Xueqing and Liu, Xuan and Khatri, Ujjwol and Wu, Jie},
title = {The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases},
journal = {Drug Resistance Updates},
year = {2023},
volume = {68},
pages = {100958},
doi = {10.1016/j.drup.2023.100958}
}
EUVIMED